PLEASE WEAR A MASK TO YOUR APPOINTMENT.
WELLNESS EXAMS, STI/STD TESTING AND ULTRASOUNDS MUST BE SCHEDULED BY PHONE. Contact Us.
By Valerie Schumacher, RN, CHC
When seeking medical treatment for any condition, you need to be educated and informed to make the best decision for yourself. There is much thought and consideration that should go into every medical procedure or medication you put into your body.
“The Abortion Pill” is a drug named Mifeprex. In 2016 it was approved by the FDA to be used with another drug misoprostol, to end a pregnancy through 70 days gestation. This means you do have some time to slow down, take a deep breath, and think through the options that are available to you. These medications can be given over a 2-3 day period, with a follow up to confirm the procedure was complete and to verify there are no complications developing. A few of the main risks include bleeding, infections, sepsis, failed abortion, undiagnosed ectopic pregnancy, and the unknown long term physical or psychological effects.1 It is in your best interest and considered best practice to verify the pregnancy, including the location of the embryo. An Ultrasound needs to be performed to gain this vital information.
At A Woman’s Place Medical Clinic, we have medical professionals on staff at all locations around the Tampa Bay Area. You may meet with a Registered Nurse or another well-trained staff member to help you find the answers to all your important questions. We offer free medical grade pregnancy testing, along with Ultrasounds, at no cost to you. A Registered Nurse or a Registered Diagnostic Medical Sonographer will guide you through the ultrasound process. We do not benefit financially in any way by your decision. We are here to help you understand the physical and emotional risks associated with a medical or surgical abortion.
1 U.S. Food and Drug Administration (2016, March 30). Full prescribing information Mifeprex (mifepristone); Warning & Precautions. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf